Related Experiment Videos
Impaired coronary vasodilatory capacity after dipyridamole administration in hypertrophic cardiomyopathy
Insights
Patients with hypertrophic cardiomyopathy (HCM) show reduced coronary blood flow and impaired vasodilation. Abnormal coronary vasculature may underlie these changes, impacting exercise capacity in HCM patients.
Area of Science:
- Cardiology
- Cardiovascular Physiology
- Medical Research
Background:
- Hypertrophic cardiomyopathy (HCM) is a genetic heart condition.
- Coronary vasodilatory capacity is crucial for myocardial oxygen supply.
- Reduced coronary vasodilation may contribute to symptoms in HCM.
Purpose of the Study:
- To investigate the mechanisms behind reduced coronary vasodilatory capacity in non-obstructive HCM patients.
- To compare coronary blood flow and resistance between HCM patients and controls.
Main Methods:
- Dipyridamole (0.56 mg/kg) was administered to 19 HCM patients and 7 controls.
- Maximum coronary blood flow and minimum coronary vascular resistance were measured.
- Correlations with left ventricular parameters and exercise tolerance were assessed.
Main Results:
- HCM patients exhibited significantly lower maximum coronary blood flow (131 vs 192 ml/100 g/min) and higher minimum coronary vascular resistance (0.64 vs 0.44 mmHg/ml/100 g/min) compared to controls.
- Minimum coronary vascular resistance correlated with left ventricular muscle mass (r=0.55).
- Reduced exercise tolerance in HCM patients was associated with lower maximum coronary blood flow and higher minimum coronary vascular resistance.
Conclusions:
- A subset of HCM patients demonstrates reduced coronary vasodilatory capacity.
- Abnormal coronary vasculature, potentially due to inadequate growth or small vessel disease, is a possible mechanism in HCM.
- Reduced coronary vasodilatory capacity may contribute to impaired exercise tolerance in HCM.
Abstract:
To investigate mechanisms for a reduced coronary vasodilatory capacity in patients with hypertrophic cardiomyopathy (HCM), maximum coronary blood flow and minimum coronary vascular resistance were measured by administering dipyridamole (0.56 mg/kg) to 19 patients with non-obstructive HCM and to 7 control subjects. The maximum coronary blood flow was significantly lower (131 +/- 46 vs 192 +/- 41 ml/100 g . min, p less than 0.01, mean +/- SD) and the minimum coronary vascular resistance was significantly higher (0.64 +/- 0.23 vs 0.44 +/- 0.13 mmHg/ml/100 g . min, p less than 0.05) in HCM patients. There were no significant correlations between maximum coronary blood flow or minimum coronary vascular resistance and the baseline left ventricular end-diastolic pressure or the severity of systolic narrowing of the left anterior descending artery of the septal perforator. In contrast, the minimum coronary vascular resistance was correlated significantly with the left ventricular muscle mass (r = 0.55, p less than 0.05), but its correlation to small coronary vessel disease could not be studied. In addition, HCM patients with a reduced exercise tolerance (less than 7 metabolic units) demonstrated a significantly lower maximum coronary blood flow and higher minimum coronary vascular resistance than control subjects. These findings suggest that: (1) there is a group of HCM patients who have a reduced coronary vasodilatory capacity, (2) abnormal coronary vasculature is a possible underlining mechanism of HCM, either due to inadequate growth unassociated with left ventricular hypertrophy or as small coronary vessel disease, and (3) a reduced coronary vasodilatory capacity.